Biotest

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: -

Established: 1946-01-01

Employees: -

Market Cap: $1.4B

Website: http://www.biotest.de

Clinical Trials

Efficacy and Safety of Trimodulin (BT588) in Subjects with Severe Community-acquired Pneumonia (sCAP)

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia

Interventions: Drug: Trimodulin
Drug: Placebo (human albumin 1%)

First Posted Date: 2023-02-10

Last Posted Date: 2024-11-28

Lead Sponsor: Biotest

Target Recruit Count: 590

Registration Number: NCT05722938

Locations: 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇭🇺
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary
🇮🇪
Beaumont Hospital, Dublin, Ireland

and more 122 locations

Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

Phase 3

Recruiting

Conditions: COVID-19
Pneumonia
Community-acquired Pneumonia
Bacterial Pneumonia
Respiratory Infection
Viral Pneumonia
Fungal Pneumonia
Acute Respiratory Distress Syndrome

Interventions: Drug: Trimodulin
Drug: Placebo (human albumin 1%)

First Posted Date: 2022-09-07

Last Posted Date: 2024-04-11

Lead Sponsor: Biotest

Target Recruit Count: 390

Registration Number: NCT05531149

Locations: 🇦🇷
Investigational Site #5402, Córdoba, Argentina
🇦🇷
Investigational Site #5403, Cordoba, Argentina
🇧🇷
Investigational Site #5506, Porto Alegre, Brazil

and more 56 locations

Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)

Phase 3

Active, not recruiting

Conditions: Congenital Cytomegalovirus Infection

Interventions: Drug: BT097

First Posted Date: 2021-12-27

Last Posted Date: 2023-10-23

Lead Sponsor: Biotest

Target Recruit Count: 80

Registration Number: NCT05170269

Locations: 🇩🇪
4902, Erlangen, Germany
🇩🇪
4903, Bonn, Germany
🇩🇪
4906, Berlin, Germany

and more 2 locations

Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: Trimodulin
Other: Placebo (human albumin 1%)

First Posted Date: 2020-10-06

Last Posted Date: 2023-01-10

Lead Sponsor: Biotest

Target Recruit Count: 166

Registration Number: NCT04576728

Locations: 🇷🇺
Investigational site # 0711, Moscow, Russian Federation
🇷🇺
Investigational site # 0707, Kemerovo, Russian Federation
🇫🇷
Investigational Site # 3301, Paris, France

and more 14 locations

Adjusted Fibrinogen Replacement Strategy

Phase 3

Completed

Conditions: Bleeding Disorder
Hypofibrinogenemia; Acquired

Interventions: Biological: BT524
Biological: FFP/Cryo

First Posted Date: 2018-02-23

Last Posted Date: 2024-10-18

Lead Sponsor: Biotest

Target Recruit Count: 339

Registration Number: NCT03444324

Locations: 🇧🇪
Site 01, Leuven, Belgium
🇧🇪
Site 02, Jette, Belgium
🇨🇿
Site 54, Brno, Czechia

and more 16 locations

This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)

Phase 3

Completed

Conditions: Immune Thrombocytopenia

Interventions: Biological: BT595

First Posted Date: 2016-08-09

Last Posted Date: 2019-08-14

Lead Sponsor: Biotest

Target Recruit Count: 34

Registration Number: NCT02859909

Locations: 🇧🇬
Investigational site # 3598, Sofia, Bulgaria
🇨🇿
Investigational site # 4202, Praha, Czechia
🇧🇬
Investigational site # 3596, Varna, Bulgaria

and more 19 locations

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Phase 3

Completed

Conditions: Primary Immunodeficiency Disease

Interventions: Biological: IgG Next Generation (BT595)

First Posted Date: 2016-06-23

Last Posted Date: 2023-07-20

Lead Sponsor: Biotest

Target Recruit Count: 81

Registration Number: NCT02810444

Locations: 🇩🇪
Investigational site # 4904, Freiburg, Germany
🇺🇸
Investigational site # 0106, South Bend, Indiana, United States
🇺🇸
Investigational site # 0114, Thornton, Colorado, United States

and more 16 locations

Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Biological: BT063
Biological: Placebo

First Posted Date: 2015-09-18

Last Posted Date: 2020-01-27

Lead Sponsor: Biotest

Target Recruit Count: 36

Registration Number: NCT02554019

Locations: 🇧🇾
Study Site 37501, Minsk, Belarus
🇷🇸
Study Site 38102, Niska Banja, Serbia
🇧🇾
Study Site 37504, Vitebsk, Belarus

and more 11 locations

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Phase 3

Completed

Conditions: Congenital Afibrinogenemia
Congenital Hypofibrinogenemia

Interventions: Biological: BT524 (fibrinogen concentrate from human plasma)

First Posted Date: 2014-02-19

Last Posted Date: 2022-07-27

Lead Sponsor: Biotest

Target Recruit Count: 36

Registration Number: NCT02065882

Locations: 🇪🇬
Site 11, Cairo, Egypt
🇩🇪
Site 16, Frankfurt, Germany
🇹🇳
Site 14, Sousse, Tunisia

and more 3 locations

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tregalizumab
Drug: Placebo

First Posted Date: 2013-12-03

Last Posted Date: 2017-08-24

Lead Sponsor: Biotest

Target Recruit Count: 321

Registration Number: NCT01999192

Locations: 🇺🇦
Study Site 07, Vinnytsia, Ukraine
🇺🇦
Study Site 01, Kharkiv, Ukraine
🇺🇦
Study Site 03, Kyiv, Ukraine

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy